Azithromycin Dosage for Typhoid Fever in Adults
For uncomplicated typhoid fever in adults, azithromycin should be administered at 500 mg (or 20 mg/kg, maximum 1 gram) orally once daily for 7 days. This represents the current standard of care based on WHO recommendations and recent high-quality evidence 1, 2.
Dosing Regimen
The recommended dosing is:
- 500 mg orally once daily for 7 days (or weight-based: 20 mg/kg/day, maximum 1 gram daily) 1, 3
- Can be administered with or without food, though food increases Cmax by 56% without affecting overall absorption (AUC) 4
- No dose adjustment needed for gender or mild-to-moderate renal impairment 4
Evidence Supporting This Recommendation
The most recent and highest-quality evidence comes from the ACT-South Asia trial (2026), which enrolled 1,847 patients across Nepal, Bangladesh, and Pakistan 3. This phase 4 randomized controlled trial demonstrated that:
- Azithromycin monotherapy achieved a 94.9% clinical cure rate in clinically suspected typhoid
- Treatment failure occurred in only 5.1% of patients
- In culture-confirmed cases, azithromycin alone had an 88.8% success rate
- Adding cefixime to azithromycin provided no additional benefit (treatment failure 11.2% vs 16.0%, p=0.20)
This definitively supports azithromycin monotherapy and argues against combination therapy for uncomplicated disease 3.
Clinical Efficacy Across Studies
Multiple studies confirm azithromycin's effectiveness:
Bangladesh trial (2021): 7-day azithromycin course showed 85% clinical cure rate with mean fever clearance time of 5.8 days, superior to both ciprofloxacin (62% cure, 8.2 days) and cefixime (71% cure, 7.1 days) 5
Vietnam trial (2008): Azithromycin 20 mg/kg/day for 7 days showed equivalent efficacy to gatifloxacin with median fever clearance of 106 hours, even against 96% nalidixic acid-resistant strains 6
Meta-analysis evidence: Azithromycin demonstrates lower risk of clinical failure (OR 0.48,95% CI 0.26-0.89) and shorter hospital stays compared to fluoroquinolones 2
Pharmacokinetic Considerations
Despite seemingly low plasma concentrations, azithromycin remains highly effective because:
- Extensive tissue distribution: Tissue concentrations exceed plasma levels by >100-fold in some tissues 4
- Intracellular accumulation: Leukocyte concentrations are >1000-fold higher than serum 4
- Prolonged half-life: Terminal elimination half-life of 68 hours allows once-daily dosing 4
A 2025 pharmacokinetic study found that despite C_max/MIC ratios of only 0.29 and AUC/MIC of 2.64, all patients achieved clinical cure with median fever clearance of 3 days and no relapses 7. This confirms that extracellular plasma levels do not predict clinical efficacy for this intracellular pathogen.
Important Clinical Caveats
Resistance concerns: While azithromycin resistance remains relatively uncommon, recent surveillance shows emerging resistance in Southeast Asia 8, 9. However:
- Disc diffusion testing shows 1.9% false-resistance rates 8
- Time-kill assays demonstrate bacteriostatic (not bactericidal) activity 8
- Clinical efficacy remains preserved even with elevated MICs up to 12 mg/L 7
When to consider alternatives or combination therapy:
- Complicated typhoid fever (intestinal perforation, severe sepsis, neurological involvement)
- Treatment failure after 7 days of azithromycin
- Documented azithromycin resistance (though clinical correlation needed given testing discrepancies)
- In these scenarios, consider ceftriaxone 2-4 grams IV daily or combination therapy with infectious disease consultation
Adverse Effects
Azithromycin is generally well-tolerated 4:
- Most common: Diarrhea/loose stools (4-5%), nausea (3%), abdominal pain (2-3%)
- Discontinuation rate due to adverse effects: <1%
- Serious adverse events are rare (<2%)
The 7-day course of azithromycin 500 mg once daily represents the optimal balance of efficacy, safety, antimicrobial stewardship, and cost-effectiveness for uncomplicated typhoid fever in adults, with no evidence supporting combination therapy or alternative regimens in uncomplicated cases 3, 5, 6.